Patents matching “angiotensin”

US 2025195525

ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jun 19, 2025 · Expires Jun 14, 2045

US 11891638

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

Northwestern University · Granted Feb 6, 2024 · Expires Feb 1, 2044

US 11447521

Compounds and methods for modulating angiotensinogen expression

Ionis Pharmaceuticals, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

US 11419942

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

US 11078471

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

Northwestern University · Granted Aug 3, 2021 · Expires Jul 29, 2041

US 10912792

Compounds and methods for modulating angiotensinogen expression

Ionis Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

US 10814007

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

US 10709728

Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

US 10443049

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

Northwestern University · Granted Oct 15, 2019 · Expires Oct 10, 2039

US 10238749

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 9670473

Crystals of angiotensin-converting enzyme (ACE)

ANGIODESIGN (UK) LIMITED · Granted Jun 6, 2017 · Expires Jun 1, 2037

US 9387249

Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Takeda Pharmaceutical Company Limited · Granted Jul 12, 2016 · Expires Jul 7, 2036

US 8895755

Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity

Theravance Biopharma R&D IP, LLC · Granted Nov 25, 2014 · Expires Nov 20, 2034

US 8569351

Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

Theravance, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

US 7378108

Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

Takeda Pharmaceutical Company Limited · Granted May 27, 2008 · Expires May 22, 2028

US 6521659

Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

The Institute for Pharmaceutical Discovery, LLC · Granted Feb 18, 2003 · Expires Feb 13, 2023

US 6420405

Pharmaceutical composition for angiotensin II-mediated diseases

Takeda Chemical Industries Ltd. · Granted Jul 16, 2002 · Expires Jul 11, 2022

US 6348481

Pharmaceutical composition for angiotensin II-mediated diseases

Takeda Chemical Industries Ltd. · Granted Feb 19, 2002 · Expires Feb 14, 2022

US 6228874

Pharmaceutical composition for angiotensin II-mediated diseases

Takeda Chemical Industries Ltd. · Granted May 8, 2001 · Expires May 3, 2021

US 6194460

Composition for treating cough induced by angiotensin converting enzyme inhibitors

Montefiore Medical Center · Granted Feb 27, 2001 · Expires Feb 22, 2021

US 6100252

Heterocyclic compounds and their use as angiotensin antagonists

Takeda Chemical Industries Ltd. · Granted Aug 8, 2000 · Expires Aug 3, 2020